.jpg)
UK biotech Juvenescence targets $150M+ for 'healthy lifespan' drug candidates
The "healthy lifespan" space is attracting more dollars. Juvenescence is out with a $76 million Series B-1, its first equity funding since before the Covid-19 pandemic. The drug development startup, headquartered in London, last outlined ...
The "healthy lifespan" space is attracting more dollars.
Juvenescence is out with a $76 million Series B-1, its first equity funding since before the Covid-19 pandemic. The drug development startup, headquartered in London, last outlined ...
